Titre:
  • Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/ macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
Auteur:Zwierzina, Heinz; Suciu, Stefan; Loeffler, Jay S.; Neuwirtova, Radana; Fenaux, Pierre; Beksac, Meral Sinan; Harousseau, Jean-Luc; Nuessler, Volkmar; Cermak, Jaroslav; Solbu, Gabriel; Willemze, Roel; De Witte, Theo; Amadori, Sergio; Stryckmans, Pierre; Bron, Dominique; Louwagie, A.; Selleslag, Dominik; Peetermans, M.; Berneman, Zwi Nisan; Coiffier, Bertrand; Thyss, Antoine; Bourhis, Jean; Fiere, Denis; Zittoun, R; Marie, Jean Pierre; Maraninchi, D.; Baumelou, E.; Lowenberg, B.; Sonnenveld, P.; Gerhartz, Heinrich; Ribeiro, Maíra Marques; Ben-Bassat, Isaac; Labar, Boris; Dardenne, Murielle
Informations sur la publication:Leukemia, 19, 11, page (1929-1933)
Statut de publication:Publié, 2005-11
Sujet CREF:Cancérologie
Sciences bio-médicales et agricoles
Mots-clés:Arabinoside
GM-CSF
Interleukin-3
Low-dose cytosine
Myelodysplastic syndrome
Phase III trial
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0887-6924
info:doi/10.1038/sj.leu.2403934
info:pii/2403934
info:scp/27644562303